<DOC>
	<DOCNO>NCT01506882</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Levetiracetam ( LEV ) use monotherapy , efficacy measure 6-month seizure freedom last evaluate dose LEV 1000 mg/day 2000 mg/day group , newly recently diagnose epilepsy subject .</brief_summary>
	<brief_title>An Open Label Study Levetiracetam Monotherapy Patients With Newly Diagnosed Focal Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Subject male female age â‰¥ 16 year Visit 1 Subjects newly recently diagnose Epilepsy experience unprovoked Partial Seizures ( IA , IB , IC ) , classifiable accord International League Against Epilepsy ( ILAE ) classification Epileptic Seizures Subjects least 2 unprovoked seizure separate minimum 48 hour year prior Visit 1 , , least 1 unprovoked seizure occur 3 month prior Visit 1 Minimum body weight 40 kg Visit 1 Subject history presence seizure type partial ( IA , IB , IC ) Subject experience type brain surgery consecutive 2 year prior Visit 1 Subject history presence know PseudoSeizures Subject treat Epilepsy Antiepileptic Drug ( AED ) within 6 month prior Visit 1 . However , acute subacute seizure treatment accept maximum use 2 week , treatment stop week prior Visit 1 Subject know clinically significant acute chronic illness , restrict : cardiac , renal , hepatic dysfunction , endocrinological , psychiatric illness , may impair reliable participation study necessitate use medication allow protocol</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>